title: Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation.
abstract: Fas (CD95) is a transmembrane molecule that induces programmed cell death (PCD) of lymphocytes. We examined its function in children with chronic thrombocytopenia, serum autoantibodies, and lymphadenopathy and/or splenomegaly. We found that T-cell lines from six of seven patients with this autoimmune/lymphoproliferative disease (ALD) were relatively resistant to PCD induced by monoclonal antibodies to Fas. By contrast, Fas function was normal in control patients with typical chronic idiopathic thrombocytopenic purpura (ITP) without lymphadenopathy. The defect was not due to decreased Fas expression, nor to over-production of soluble forms of Fas. Moreover, it specifically involved the Fas system because PCD was induced in the normal way by methylprednisolone. Complementary DNA sequencing of the Fas gene did not identify any causal mutation in patients with ALD. This distinguished them from patients with the human autoimmune lymphoproliferative syndrome (ALPS), who carry mutations of the Fas gene. Moreover, patients with ALD did not show the peripheral expansion of CD4/CD8 double-negative T cells that characterizes the ALPS phenotype. Fas signaling involves activation of a sphingomyelinase-catalyzing production of ceramide. We found that ceramide-induced PCD was defective in patients with ALD and not in patients with typical chronic ITP. These data suggest that the ALD patient defect involves the Fas signaling pathway downstream from the sphingomyelinase and that Fas gene mutations and double-negative T-cell expansion are not the only signs of a defective Fas system.
authors.affiliation: Dipartimento di Scienze Mediche, Università di Torino, Novara, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Dianzani
authors.forename: M
authors.initials: M
authors.lastname: Bragardo
authors.forename: D
authors.initials: D
authors.lastname: DiFranco
authors.forename: C
authors.initials: C
authors.lastname: Alliaudi
authors.forename: P
authors.initials: P
authors.lastname: Scagni
authors.forename: D
authors.initials: D
authors.lastname: Buonfiglio
authors.forename: V
authors.initials: V
authors.lastname: Redoglia
authors.forename: S
authors.initials: S
authors.lastname: Bonissoni
authors.forename: A
authors.initials: A
authors.lastname: Correra
authors.forename: I
authors.initials: I
authors.lastname: Dianzani
authors.forename: U
authors.initials: U
authors.lastname: Ramenghi
mesh_terms: D000293:Adolescent; D000328:Adult; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics*; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology*; D002518:Ceramides / Q000494:pharmacology; D002675:Child, Preschool; D003241:Consanguinity; D004252:DNA Mutational Analysis; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D006801:Humans; D007223:Infant; D008213:Lymphocyte Activation / Q000187:drug effects; D008232:Lymphoproliferative Disorders / Q000235:genetics / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology; D018807:Polymorphism, Single-Stranded Conformational; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology; D015398:Signal Transduction; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013921:Thrombocytopenia / Q000235:genetics / Q000276:immunology*; D019014:fas Receptor / Q000235:genetics / Q000502:physiology*
chemical_list: D002518:Ceramides; D018076:DNA, Complementary; D019014:fas Receptor; D013108:Sphingomyelin Phosphodiesterase; D008775:Methylprednisolone